Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.
The idea of breast cancer prevention by hormonal means stemmed from the results of treatment trials, many of them carried out by the National Surgical Adjuvant Breast and Bowel Project (NSABP). Over the years, a number of NSABP treatment studies demonstrated that breast cancer recurrence was reduced in women with the disease who were given tamoxifen, a selective estrogen receptor (ER) modulator (SERM). Five subsequent tamoxifen prevention trials with this agent have shown a 48% reduction in ER-positive cancers, but no effect for ER-negative cancers, and an increase in endometrial cancer and thromboembolic events. The drug raloxifene, another SERM, originally examined as an osteoporosis agent, has also shown promise for the prevention of breast cancer, although, as with tamoxifen, the drug carries a risk for thromboembolic events. There is recent evidence in a large treatment trial that the aromastase inhibitor anastrazole, a 'pure anti-estrogen', holds promise as a breast cancer preventive agent. Longer follow-up and the testing of additional agents is required before these drugs can be used widely for prevention. In addition, future research should focus on the identification of at-risk women who can perhaps be targeted for specific prevention agents.
D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D015994:Incidence; D009361:Neoplasm Invasiveness; D011960:Receptors, Estrogen / Q000187:drug effects / Q000502:physiology; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D014481:United States
D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators